PCI Pharma Services, a pharma supply chain solutions provider, has acquired Canada-based pharma packaging company Bellwyck Pharma Services for an undisclosed price.

Bellwyck Pharma Services has been serving the clinical trial and commercial drug markets with primary and secondary packaging and labeling for 25 years.

Its acquisition will give four GMP-compliant facilities for PCI Pharma Services in the US, Germany, and Canada, thereby helping the latter in boosting its global footprint in key markets.

Commenting on PCI acquisition of Bellwyck Pharma, Salim Haffar – CEO of PCI Pharma Services, said: “We are thrilled to welcome the Bellwyck team into the PCI family. Their passion for patients, talented team and innovative approach to client challenges is perfectly aligned to our purpose and global strategy as PCI strives to be the bridge between life-changing therapies and patients around the world.

“We are particularly excited that this acquisition will expand our clinical business worldwide and provide our clients with access to sites in continental Europe and Canada, in addition to our existing facilities.”

The clinical and commercial supply chain solutions of Bellwyck Pharma Services are said to mirror the existing core capabilities of PCI Pharma Services, which includes extensive clinical trial packaging, labeling, and logistics for phase I-IV studies and also full-service commercial packaging.

Through the addition of the Canadian pharma packaging company, PCI Pharma Services will now have 25 GMP facilities in North America, Europe, and Asia-Pacific, while having a workforce of more than 3,700 people.

Jeff Sziklai – CEO of Bellwyck Pharma Services, commenting on PCI acquisition of Bellwyck Pharma, said: “We are delighted that Bellwyck is joining the PCI team and anticipate a seamless integration for our employees and clients.

“We have a shared focus on innovation, quality, exceptional service and our employees. Joining forces with a global industry leader, such as PCI, is a great step forward for Bellwyck. We look forward to helping accelerate the global growth of PCI’s clinical business, leveraging our reputation for innovative, customized clinical trial solutions for our clients.”

The addition of the Canadian pharma packaging company is the third acquisition of PCI Pharma Services in three years outside of the US.

Based in Philadelphia, PCI Pharma Services is owned principally by Partners Group on behalf of its clients, alongside partner investors Thomas H. Lee Partners and Frazier Healthcare.

Bellwyck Pharma Services had used the services of PricewaterhouseCoopers Corporate Finance as its financial advisor on the deal.

  Bellwyck Pharma Services, Canada, Jeff Sziklai, PCI Pharma Services, Pharma acquisition news, Philadelphia, Salim Haffar, USA